PET scans use fluorodeoxyglucose (FDG), a radioactive form of glucose, to show how aggressively tumours consume glucose ...

Prolonged rapid eye movement latency may be a potential marker for Alzheimer disease and Alzheimer disease and related dementias.

Researchers from Astrazeneca plc and Karolinska Institutet have described the positron emission tomography (PET) evaluation of [11C]AZD-2423, a chemokine receptor type 2 (CCR2) radioligand in ...

With the aim to add a “revenue generating CDMO arm,” Lantheus Holdings has bought New Jersey-based radiopharmaceutical ...

Prolonged rapid eye movement sleep latency may be an early indicator of Alzheimer’s disease and related dementias, according ...

Finnish biopharmaceutical company Aplagon has secured a financing of €7m ($7.24m) to advance its heparin proteoglycan mimetic ...

Horseheads senior athlete appreciative of support from family, community and medical staff in his battle against cancer.

Innovative research for a dog cancer treatment from the University of Missouri College of Veterinary Medicine has shown early ...

Instead, patients are often told directly or indirectly that there is “nothing wrong” or that “it’s all in your head.” There is a big difference between a test result that does not reveal an ...

All the experts say socializing, ideally while doing that intellectual activity, can help a lot, because it not only ...

(HealthDay News) — Appropriate use criteria (AUC) for the use of amyloid and tau positron emission tomography (PET) have been issued by the Alzheimer’s Association and the Society for Nuclear Medicine ...

Lantheus is acquiring radiopharmaceutical CDMO Evergreen Theragnostics in a deal worth up to $1 billion, expanding its manufacturing capabilities and drug pipeline. The acquisition includes Octevy, a ...